Eli Lilly and Company (NYSE:LLY - Get Free Report) shares were up 1.9% during trading on Monday . The stock traded as high as $801.97 and last traded at $800.72. Approximately 1,067,866 shares were traded during trading, a decline of 73% from the average daily volume of 4,014,303 shares. The stock had previously closed at $785.41.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on LLY. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a report on Monday, November 4th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, January 22nd. Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research note on Thursday, October 10th. Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price target on the stock. Finally, Barclays lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating for the company in a research report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,002.22.
Check Out Our Latest Analysis on LLY
Eli Lilly and Company Price Performance
The firm's 50 day moving average price is $776.69 and its two-hundred day moving average price is $848.19. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market cap of $767.20 billion, a PE ratio of 87.37, a P/E/G ratio of 1.59 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm's quarterly revenue was up 20.4% compared to the same quarter last year. On average, research analysts expect that Eli Lilly and Company will post 12.98 earnings per share for the current year.
Eli Lilly and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.74%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.
Eli Lilly and Company announced that its Board of Directors has initiated a share buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its stock is undervalued.
Insider Buying and Selling
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders.
Institutional Trading of Eli Lilly and Company
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Consolidated Portfolio Review Corp lifted its stake in Eli Lilly and Company by 537.0% during the fourth quarter. Consolidated Portfolio Review Corp now owns 6,822 shares of the company's stock worth $5,266,000 after purchasing an additional 5,751 shares during the last quarter. Hedeker Wealth LLC lifted its position in Eli Lilly and Company by 9.8% in the 4th quarter. Hedeker Wealth LLC now owns 1,930 shares of the company's stock worth $1,490,000 after buying an additional 173 shares during the last quarter. Eagle Ridge Investment Management boosted its stake in Eli Lilly and Company by 12.1% in the fourth quarter. Eagle Ridge Investment Management now owns 1,450 shares of the company's stock worth $1,119,000 after buying an additional 156 shares in the last quarter. Telos Capital Management Inc. grew its position in Eli Lilly and Company by 23.0% during the fourth quarter. Telos Capital Management Inc. now owns 1,987 shares of the company's stock valued at $1,534,000 after acquiring an additional 371 shares during the last quarter. Finally, Silver Oak Securities Incorporated raised its stake in shares of Eli Lilly and Company by 26.9% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,475 shares of the company's stock worth $1,915,000 after acquiring an additional 524 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
